Biophan to Host Conference Call to Discuss Product Development and Progress in Monetizing Intellectual Property Portfolio; Company to Update Investors on Business Development Progress
Senior Biophan officers including CEO Michael Weiner will discuss the strategic initiatives within the Company's Business Development Group, which was formed in August to accelerate the generation of revenues through Biophan's intellectual property portfolio and to develop technology-based products for important healthcare market segments.
“Biophan's business strategy is based on the commercialization of our broad intellectual property portfolio”
"Biophan's business strategy is based on the commercialization of our broad intellectual property portfolio," said Mr. Weiner. "Toward that end we recently formed the Biophan Business Development Group to accelerate and expand our activities to license our extensive IP portfolio to leading biomedical product manufacturers. Monday's conference call will enable us to provide the maximum amount of information to investors and other interested parties about our progress in commercializing our intellectual property and product portfolio."
Biophan is a biomedical development leader with a powerful intellectual property portfolio of 156 U.S. patents, licenses, or applications and 46 international applications. These patents include technologies to enable a variety of products and solutions within various multi-billion-dollar segments of the biomedical marketplace, including Magnetic Resonance Imaging (MRI) safety and image compatibility, and advanced drug-delivery and drug-elution technologies. Among the Company's recent product initiatives is a measure to expand its presence in cardiovascular diagnostic and therapeutic devices, one of the fastest-growing segments of the biomedical industry, with an expected value of nearly $28 billion before the end of this decade.
To connect to the conference call in the United States, please dial (800) 288-8967. International callers can dial (612) 332-0725. When prompted, please tell the operator that you would like to connect to the "Biophan Teleconference" call. This call is free of charge to all interested investors.
About Biophan Technologies
Biophan develops and markets cutting-edge technologies designed to make biomedical devices safe and image compatible with the magnetic resonance imaging (MRI) environment. The Company develops technologies that enable implanted medical systems such as pacemakers, interventional surgical devices such as catheters and guidewires, and devices such as stents to be safely and effectively imaged under MRI. Biophan is developing these same technologies to provide new MRI contrast agents. Other applications include drug delivery and power systems derived from body heat. Four Biophan technologies include advances in nanotechnology and thin film coatings. Committed to growth through innovation and developmental leadership, Biophan and its licensors now hold a total of 156 U.S. patents, licenses, or applications. This total includes 42 issued U.S. patents, 8 recently-allowed applications that will issue as patents in the near future, and 106 pending applications at various stages of examination at the U.S. Patent and Trademark Office, plus international applications. The patents cover areas including nanotechnology (nanomagnetic particle coatings), medical device designs, radio frequency filters, polymer composites, thermoelectric materials for batteries generating power from body heat, and photonics. Biophan has joint development and licensing agreements with Boston Scientific and NASA's Ames Center for Nanotechnology. Biophan's goal is to make all biomedical devices capable of safely and successfully working with MRI, and delivering other technologies which will improve quality of life. Biophan is also listed on the Frankfurt Stock Exchange under the ticker symbol "BTN." For more information, please visit www.biophan.com.
Cautionary Statement Regarding Forward-Looking Statements
Certain statements included in this press release may constitute forward-looking statements within the meaning of applicable securities laws. These statements reflect what Biophan anticipates, expects, or believes may happen in the future. Biophan's actual results could differ materially from the outcome or circumstance expressed or implied by such forward-looking statements as a result of a variety of factors including, but not limited to: Biophan's ability to develop its technologies; the approval of Biophan's patent applications; the successful implementation of Biophan's research and development programs; the ability of Biophan to demonstrate the effectiveness of its technology; the acceptance by the market of Biophan's technology and products incorporating such technology, the ability of Biophan to effectively negotiate and enter into contracts with medical device manufacturers for the licensing of Biophan's technology; competition; the ability of Biophan to raise capital to fund its operating and research and development activities until it generates revenues sufficient to do so; and the timing of projects and trends in future operating performance, as well as other factors expressed from time to time in Biophan's periodic filings with the Securities and Exchange Commission (the "SEC"). As a result, this press release should be read in conjunction with Biophan's periodic filings with the SEC which are incorporated herein by reference. The forward-looking statements contained herein are made only as of the date of this press release, and Biophan undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.